Dr. Michael  Schnekenburger

Dr. Michael Schnekenburger

Research Director/VP of Research
Laboratory of Molecular and Cellular Biology of Cancer, Luxembourg


Highest Degree
Ph.D. in Cellular and Molecular Biology from University of Reims-Champagne-Ardenne, France

Share this Profile

Biography

Dr. Michael Schnekenburger is currently working as Team Leader of Cancer Epigenetics research group within the LBMCC, directed by Dr. Marc Diederich, Luxembourg. He has completed his Ph.D. in Cellular and Molecular Biology from University of Reims-Champagne-Ardenne, France, and Post Doctoral Fellow at the Department of Environmental Health of the University of Cincinnati (OH, USA). He is also serving as member of editorial board in International Journal of Genetics and Genomics, Vedic Research International journals, and Austin Journal of Genetics and Genomic Research. He is also acting as peer reviewer for Biochemical Pharmacology, Leukemia Research, Journal of Cell Communication and Signaling, International Journal of Cell Biology, International Journal of Genetics and Genomics, European Journal of Molecular Biology, Cancer Research Journal and many others. He has published 60 research articles in journals contributed as author/co-author.

Area of Interest:

Molecular Sciences
100%
Tumorigenesis
62%
DNA Methylation
90%
Histone Modifications
75%
Molecular Biology
55%

Education

2004

Ph.D.

University of Reims-Champagne-Ardenne, France

Cellular and Molecular Biology

Selected Publications

  1. Seidel, C., M. Schnekenburger, A. Mazumder, M.H. Teiten, G. Kirsch, M. Dicato and M. Diederich, 2016. 4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer. Biochem. Pharmacol., 99: 31-52.
    CrossRef  |  Direct Link  |  

  2. Schnekenburger, M., C. Florean, M. Dicato and M. Diederich, 2016. Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments. Curr. Top. Med. Chem., 16: 745-776.
    Direct Link  |  

  3. Schnekenburger, M. and M. Diederich, 2016. DNA methylation and demethylation mechanisms as therapeutic targets? Curr. Top. Med. Chem., 16: 807-808.

  4. Koprinarova, M., M. Schnekenburger and M. Diederich, 2016. Role of histone acetylation in cell cycle regulation. Curr. Top. Med. Chem., 16: 732-744.
    Direct Link  |  

  5. Seidel, C., M. Schnekenburger, M. Dicato and M. Diederich, 2015. Histone deacetylase 6 in health and disease. Epigenomics, 7: 103-118.
    CrossRef  |  Direct Link  |  

  6. Schnekenburger, M., C. Florean, C. Grandjenette and M. Diederich, 2015. Editorial: Novel pharmaceutical approaches by natural compound-derived epigenetic regulators: epigenetic readers, writers and erasers as therapeutic targets. Curr. Top. Med. Chem., 16: 677-679.
    Direct Link  |  

  7. Poplineau, M., M. Schnekenburger, J. Dufer, A. Kosciarz and S. Brassart‐Pasco et al., 2015. The DNA hypomethylating agent, 5‐aza‐2'‐deoxycytidine, enhances tumor cell invasion through a transcription-dependent modulation of MMP-1 expression in human fibrosarcoma cells. Mol. Carcinogenesis, 54: 24-34.
    CrossRef  |  Direct Link  |  

  8. Grandjenette, C., M. Schnekenburger, F. Morceau, F. Mack and K. Wiechmann et al., 2015. Dual induction of mitochondrial apoptosis and senescence in chronic myelogenous leukemia by myrtucommulone A. Anti-Cancer Agents Med. Chem. (Formerly Curr. Med. Chem.-Anti-Cancer Agents), 15: 363-373.
    Direct Link  |  

  9. Valente, S., Y. Liu, M. Schnekenburger, C. Zwergel and S. Cosconati et al., 2014. Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells. J. Med. Chem., 57: 701-713.
    CrossRef  |  Direct Link  |  

  10. Trecul, A., F. Morceau, A. Gaigneaux, M. Schnekenburger, M. Dicato and M. Diederich, 2014. Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. Biochem. Pharmacol., 92: 299-311.
    CrossRef  |  Direct Link  |  

  11. Talhi, O., M. Schnekenburger, J. Panning, D.G. Pinto and J.A. Fernandes et al., 2014. Bis (4-hydroxy-2H-chromen-2-one): Synthesis and effects on leukemic cell lines proliferation and NF-κB regulation. Bioorganic Med. Chem., 22: 3008-3015.
    CrossRef  |  Direct Link  |  

  12. Seidel, C., M. Schnekenburger, M. Dicato and M. Diederich, 2014. Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases. Cancer Lett., 343: 134-146.
    CrossRef  |  Direct Link  |  

  13. Seidel, C., M. Schnekenburger, C. Zwergel, F. Gaascht and A. Mai et al., 2014. Novel inhibitors of human histone deacetylases: Design, synthesis and bioactivity of 3-alkenoylcoumarines. Bioorganic Med. Chem. Lett., 24: 3797-3801.
    CrossRef  |  Direct Link  |  

  14. Schnekenburger, M., M. Dicato and M. Diederich, 2014. Plant-derived epigenetic modulators for cancer treatment and prevention. Biotechnol. Adv., 32: 1123-1132.
    CrossRef  |  Direct Link  |  

  15. Schnekenburger, M., M. Dicato and M. Diederich, 2014. Epigenetic modulators from The Big Blue: A treasure to fight against cancer. Cancer Lett., 351: 182-197.
    CrossRef  |  Direct Link  |  

  16. Schnekenburger, M. and M. Diederich, 2014. Modulation of epigenetic mechanisms for anti-cancer intervention-New challenges and perspectives. Austin J. Genet. Genomic Res., 1: 1-2.

  17. Rotili, D., D. Tarantino, B. Marrocco, C. Gros and V. Masson et al., 2014. Properly substituted quinazoline analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity. PLoS One, Vol. 2014. 10.1371/journal.pone.0096941.
    CrossRef  |  

  18. Kurita, H., M. Schnekenburger, J.L. Ovesen, Y. Xia and A. Puga, 2014. The Ah receptor recruits IKKα to its target binding motifs to phosphorylate serine-10 in histone H3 required for transcriptional activation. Toxicol. Sci., 139: 121-132.
    CrossRef  |  Direct Link  |  

  19. Grandjenette, C., M. Schnekenburger, T. Karius, J. Ghelfi and A. Gaigneaux et al., 2014. 5-aza-2'-deoxycytidine-mediated c-myc Down-regulation triggers telomere-dependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia. Neoplasia, 16: 511-528.
    CrossRef  |  Direct Link  |  

  20. Poplineau, M., C. Doliwa, M. Schnekenburger, F. Antonicelli, M. Diederich, A. Trussardi-Regnier and J. Dufer, 2013. Epigenetically-induced changes in nuclear textural patterns affect gelatinase expression in human fibrosarcoma cells. Cell. Prolif., 46: 127-136.
    PubMed  |  

  21. El Amrani, M., D. Lai, A. Debbab A.H. Aly and K. Siems et al., 2013. Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum. J. Nat. Prod., 77: 49-56.
    CrossRef  |  Direct Link  |  

  22. Seidel, C., M. Schnekenburger, M. Dicato and M. Diederich, 2012. Histone deacetylase modulators provided by mother nature. Genes Nutr., 7: 357-367.
    PubMed  |  

  23. Seidel, C., C. Florean, M. Schnekenburger and M. Diederich, 2012. Chromatin modifying agents in anticancer therapy. Biochimie, 94: 2264-2279.
    CrossRef  |  Direct Link  |  

  24. Schnekenburger, M. and M. Diederich, 2012. Epigenetics offer new horizons for colorectal cancer prevention. Curr. Colorectal. Cancer Rep., 8: 66-81.
    PubMed  |  

  25. Orlikova, B., M. Schnekenburger, M. Zloh, M. Diederich and D. Tasdemir, 2012. Natural chalcones as dual inhibitors of HDAC and NF-κB. Oncol. Rep., 28: 797-805.
    PubMed  |  

  26. Karius, T., M. Schnekenburger, M. Dicato and M. Diederich, 2012. MicroRNAs in cancer management and their modulation by dietary agents. Biochem. Pharmacol., 83: 1591-1601.
    CrossRef  |  PubMed  |  

  27. Charlet, J., M. Schnekenburger, K.W. Brown and M. Diederich, 2012. DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochem. Pharmacol., 83: 858-865.
    PubMed  |  

  28. Schumacher, M., T. Juncker, M. Schnekenburger, F. Gaascht and M. Diederich, 2011. Natural compounds as inflammation inhibitors. Genes Nutr., 6: 89-92.
    Direct Link  |  

  29. Schnekenburger, M., T. Karius, C. Cerella and M. Diederich, 2011. Targeting inflammatory cell signaling mechanisms: A promising road to new therapeutic agents in chemoprevention and cancer therapy. J. Exp. Ther. Onco., 9: 1-4.
    PubMed  |  

  30. Schnekenburger, M., C. Grandjenette, J. Gelfi, T. Karius, B. Foliguet, M. Dicato and M. Diederich, 2011. Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence and autophagy. Biochem. Pharmacol., 81: 364-378.
    PubMed  |  

  31. Schnekenburger, M., C. Florean, C. Grandjenette, M. Dicato and M. Diederich, 2011. Epigenomics of leukemia: From mechanisms to therapeutic applications. Epigenomics, 3: 581-609.
    PubMed  |  

  32. Schnekenburger, M. and M. Diederich, 2011. Omic technologies in human disease: Extending the network of epigenetic control. Epigenomics, 3: 539-541.
    PubMed  |  

  33. Ovesen, J.L., M. Schnekenburger and A. Puga, 2011. Aryl hydrocarbon receptor ligands of widely different toxic equivalence factors induce similar histone marks in target gene chromatin. Toxicol. Sci., 121: 123-131.
    PubMed  |  

  34. Karius, T., M. Schnekenburger, J. Gelfi, J. Walter, M. Dicato and M. Diederich, 2011. Reversible epigenetic fingerprint-mediated glutathione-S-transferase P1 gene silencing in human leukemia cell lines. Biochem. Pharmacol., 81: 1329-1342.
    PubMed  |  

  35. Juncker, T., C. Cerella, M.H. Teiten, F. Morceau and M. Schumacher et al., 2011. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem. Pharmacol., 81: 13-23.
    PubMed  |  

  36. Chateauvieux, S., S. Eifes, F. Morceau, M. Schnekenburger, E. Henry, M. Dicato and M. Diederich, 2011. Valproic Acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway via inhibition of GATA-1 and activation of PU.1. Biochem. Pharmacol., 81: 498-509.
    PubMed  |  

  37. Cerella, C., C. Sobolewski, S. Chateauvieux, E. Henry and M. Schnekenburger et al., 2011. COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells. Biochem. Pharmacol., 82: 1277-1290.
    PubMed  |  

  38. Nunes, M.J., I. Milagre, M. Schnekenburger, M.J. Gama, M. Diederich and E. Rodrigues, 2010. SP proteins have a critical role in histone deacvetylase inhibitor-mediated derepression of CYP46A1 gene transcription. J. Neurochem., 113: 418-431.
    Direct Link  |  

  39. Folmer, F., B. Orlikova, M. Schnekenburger, M. Dicato and M. Diederich, 2010. Naturally occurring regulators of histone acetylation/deacetylation. Curr. Nutr. Food Sci., 6: 78-99.
    Direct Link  |  

  40. Schnekenburger, M., M.A. Sartor, J.L. Marlowe, J.F. Reichard and Y. Wang et al., 2009. Genomewide analysis of aryl hydrocarbon receptor binding targets reveals an extensive array of gene clusters that control morphogenetic and developmental programs. Environ. Health Perspect., 117: 1139-1146.
    PubMed  |  

  41. Reuter, S., M. Schnekenburger, S. Cristofanon, I. Buck and M.H. Teiten et al., 2009. Tumor necrosis factor alpha induces gamma-glutamyltransferase expression via nuclear factor-κB in cooperation with Sp1. Biochem. Pharmacol., 77: 397-411.
    PubMed  |  

  42. Puga, A. and M. Schnekenburger, 2009. Epigenetic regulation of drug metabolism genes. Drug Metab. Rev., 41: 8-9.

  43. Peng, L., C.N. Mayhew, M. Schnekenburger, E.S. Knudsen and A. Puga, 2008. Repression of Ah receptor and induction of transforming growth factor-β genes in DEN-induced mouse liver tumors. Toxicolgy, 246: 242-247.
    PubMed  |  

  44. Schnekenburger, M., L. Peng and A. Puga, 2007. HDAC1 bound to the Cyp1a1 promoter blocks histone acetylation associated with Ah receptor-mediated transactivation. Biochim. Biophys. Acta, 1769: 569-578.
    PubMed  |  

  45. Schnekenburger, M., G. Talaska and A. Puga, 2007. Chromium cross-links histone deacetylase 1-DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation. Mol. Cell Biol., 27: 7089-7101.
    PubMed  |  

  46. Reichard, J.F., M. Schnekenburger and A. Puga, 2007. Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem. Biophys. Res. Commun., 352: 188-192.
    PubMed  |  

  47. Schnekenburger, M., F. Morceau, E. Henry, R. Blasius, M. Dicato, C. Trentesaux and M. Diederich, 2006. Transcriptional and post-transcriptional regulation of glutathione S-transferase P1 expression during butyric acid-induced differentiation of K562 cells. Leuk Res., 30: 561-568.
    PubMed  |  

  48. Morceau, F., M. Schnekenburger, R. Blasius, I. Buck, M. Dicato and M. Diederich, 2006. Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1. Cancer Lett., 240: 203-212.
    PubMed  |  

  49. Duvoix, A., R. Blasius, S. Delhalle, M. Schnekenburger and F. Morceau et al., 2005. Chemopreventive and therapeutic effects of curcumin. Cancer Lett., 223: 181-190.
    CrossRef  |  PubMed  |  Direct Link  |  

  50. Schnekenburger, M., F. Morceau, A. Duvoix, S. Delhalle, C. Trentesaux, M. Dicato and M. Diederich, 2004. Increased glutathione S-transferase P1-1 expression by mRNA stabilization in hemin-induced differentiation of K562 cells. Biochem. Pharmacol., 68: 1269-1277.
    PubMed  |  

  51. Morceau, F., M. Schnekenburger, M. Dicato and M. Diederich, 2004. GATA-1: Friends, brothers and co-workers. Ann. NY Acad. Sci., 1030: 537-554.
    PubMed  |  

  52. Morceau, F., A. Duvoix, S. Delhalle, M. Schnekenburger, M. Dicato and M. Diederich, 2004. Regulation of glutathione S-transferase P1-1 gene expression by NF-kappaB in tumor necrosis factor alpha-treated K562 leukemia cells. Biochem. Pharmacol., 67: 1227-1238.
    PubMed  |  

  53. Duvoix, A., S. Delhalle, R. Blasius, M. Schnekenburger and F. Morceau et al., 2004. Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition. Biochem. Pharmacol., 68: 1101-1111.
    PubMed  |  

  54. Duvoix, A., M. Schnekenburger, S. Delhalle, R. Blasius and P. Borde-Chiche et al., 2004. Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. Cancer Lett., 216: 207-219.
    PubMed  |  

  55. Blasius, R., A. Duvoix, F. Morceau, M. Schnekenburger and S. Delhalle et al., 2004. Curcumin stability and its effect on GSTP1-1 mRNA expression in K562 cells. Ann. NY Acad. Sci., 1030: 441-448.

  56. Schnekenburger, M., F. Morceau, A. Duvoix, S. Delhalle, C. Trentesaux, M. Dicato and M. Diederich, 2003. Expression of glutathione S-transferase P1-1 in differentiating K562: Role of GATA-1. Biochem. Biophys. Res. Commun., 311: 815-821.
    PubMed  |  

  57. Duvoix, A., M. Schmitz, M. Schnekenburger, M. Dicato, F. Morceau, M.M. Galteau and M. Diederich, 2003. Transcriptional regulation of glutathione S-transferase P1-1 in human leukemia. Biofactors, 17: 131-138.
    PubMed  |  Direct Link  |  

  58. Duvoix, A., F. Morceau, S. Delhalle, M. Schmitz and M. Schnekenburger et al., 2003. Induction of apoptosis by curcumin: Mediation by glutathione S-transferase P1-1 inhibition. Biochem. Pharmacol., 66: 1475-1483.
    PubMed  |  

  59. Duvoix, A., F. Morceau, M. Schnekenburger, S. Delhalle, M.M. Galteau, M. Dicato and M. Diederich, 2003. Curcumin-induced cell death in two leukemia cell lines: K562 and Jurkat. Ann. NY Acad. Sci., 101: 389-392.
    PubMed  |  

  60. Delhalle, S., A. Duvoix, M. Schnekenburger, F. Morceau, M. Dicato and M. Diederich, 2003. An introduction to the molecular mechanisms of apoptosis. Ann. NY Acad. Sci., 1010: 1-8.
    PubMed  |